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Abstract    
 
Purpose: Muscle weakness in long-stay ICU patients contributes to 1-year mortality. Whether 
electrophysiological screening is an alternative diagnostic tool also in unconscious/uncooperative patients 
remains unknown. We aimed to determine the diagnostic properties of abnormal compound muscle action 
potential (CMAP), sensory nerve action potential (SNAP) and spontaneous electrical activity (SEA) for MRC-
defined weakness and their predictive value for 1-year mortality. 
Methods: Data were prospectively collected during the EPaNIC trial (ClinicalTrials.gov:NCT00512122). First, 
sensitivity, specificity, positive (PPV) and negative predictive values (NPV) of abnormal CMAP, SNAP and 
SEA for weakness were determined. Subsequently, association between 1-year mortality and abnormal findings 
on electrophysiological screening was assessed by univariate and multivariate analyses correcting for weakness 
and other risk factors and the prediction model involved only a development phase.  
Results: 730 patients were electrophysiologically screened of whom 432 were tested for weakness. On day 8, 
normal CMAP excluded weakness with a high NPV (80.5%). By day 15, abnormal SNAP and the presence of 
SEA revealed a high PPV (91.7% and 80.0%, respectively). Only a reduced CMAP on day 8 was associated with 
higher 1-y mortality [35.6% versus 15.2% (p<0.001)]. This association remained significant after correction for 
weakness and other risk factors [OR:2.463 (95%CI:1.113-5.452), p=0.026]. Also among conscious/cooperative 
patients without weakness, reduced CMAP was independently associated with a higher likelihood of death 
occurring during 1 year [HR:2.818 (95%CI:1.074-7.391), p=0.035].  
Conclusions: The diagnostic properties of electrophysiological screening vary over time. Abnormal CMAP 
documented early during critical illness carries information about longer-term outcome, which should be further 
investigated mechanistically.  
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INTRODUCTION 
 
 
Critically ill patients often develop weakness due to functional and structural alterations in nerves, muscles or 
both. The diagnosis of ICU-acquired neuromuscular disorders is primarily based on clinical strength assessment, 
using the Medical Research Council (MRC) sum-score [1, 2]. This score quantifies strength in 6 muscle groups 
bilaterally, with a summed score <48 indicating clinically relevant weakness [2, 3]. About 50% of patients with 
sepsis, multiple organ failure or requiring prolonged mechanical ventilation suffer from weakness [4]. 
Association studies suggested that weakness is a burden in the acute [3, 5-8] and chronic phase of critical illness 
[9, 10]. Recently, we showed that weakness present after one week of critical illness contributes to ICU and 
hospital morbidity, increased hospitalization costs and 1-year mortality [8].  
 
The MRC-based diagnosis requires patients to be awake and cooperative. Between 22% and 53% of patients [3, 
6, 7, 11] therefore remain clinically not assessable in the ICU. Electrophysiological screening including the 
quantification of compound muscle action potentials (CMAP), sensory nerve action potentials (SNAP) and the 
presence of spontaneous electrical activity (SEA), here could serve as an alternative diagnostic tool (Figure 1) 
[12-14].  However, diagnostic properties of abnormal CMAP, SNAP and SEA for weakness in the ICU are not 
well characterized. Additionally, electrophysiological features could reflect other pathophysiological alterations, 
evoked by critical illness or pre-existing, that could be important for survival, related to or independent of 
weakness [15].  
 
In this large prospective study, we determined the diagnostic properties of abnormal CMAP, SNAP and SEA for 
MRC-defined weakness after one and two weeks of critical illness. We hypothesized that abnormal CMAP, 
SNAP or SEA upon electrophysiological screening 1 week after ICU admission relate to longer-term mortality, 
and assessed whether these associations depend on the presence of weakness as well as on baseline 
characteristics and exposure to ICU-related risk factors prior to electrophysiological screening. This is a 
development-only phase of a prognostic prediction model, aimed to specifically address the independent role of 
electrophysiological characteristics for 1-year mortality [16]. 
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METHODS 
 
 
The trial protocol and consent forms were approved by the institutional ethical review board (ML4190). 
 
Patients 
 
This study is a preplanned sub-analysis of the EPaNIC trial [17], which included 4640 patients and examined 
early versus late administration of parenteral nutrition to supplement insufficient enteral nutrition in critically ill 
patients [18]. Identification of risk factors for 1-year mortality (see statistical analyses) was done in the total 
EPaNIC population.  
 
From October 2008 onwards, patients requiring intensive care for ≥8 days, further referred to as long-stay 
patients, received systematic electrophysiological screening once weekly, until ICU discharge or death. We a 
priori selected these patients for screening because of their increased risk of developing weakness. The first 
evaluation was planned on day 8 (±1 day for feasibility reasons). As it is unknown to what extent ICU patients 
with favorable clinical evolution have electrophysiological abnormalities, we also included a random sample of 
short-stay patients discharged alive from the ICU but still in hospital at day 8. The random sample was 
computer-generated in a 1/10 ratio and stratified according to diagnostic admission categories. These patients 
received electrophysiological screening on day 8±1 on the ward (Figure 2). From December 2008 onwards, 
MRC sum-score was systematically assessed 3 times weekly in awake long-stay patients [8, 11]. Also here, a 
random sample of short-stay patients was included. Patients with neuromuscular disorders identified prior to ICU 
admission, or in whom this was the reason for ICU admission were excluded (see online supplement). Other 
exclusion criteria were patient refusal, unavailability of patient/assessor at planned examination, and decrement 
on repetitive nerve stimulation, indicating neuromuscular blocking.  
 
Electrophysiological tests 
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For nerve conduction studies, 1 standard motor and 1 sensory nerve were evaluated in both upper and lower 
limbs unilaterally. We defined reduced CMAP and SNAP when below the lower limit of normal in both nerves 
of both limbs [19]. Needle electromyography in rest was performed unilaterally in 1 standard proximal and 1 
distal muscle in both upper and lower limbs. Abundant SEA was defined as the presence of sustained fibrillation 
potentials and/or positive sharp waves in at least 2 muscles of at least 2 limbs. (see online supplement) 
 
MRC sum-score 
 
The MRC sum-score was evaluated as described [11, 20] and assessed by physiotherapists blinded for 
electrophysiological data (see online supplement). 
 
Statistical analyses 
 
Data were analyzed using IBM SPSS-20 (SPSS Inc). Baseline and outcome variables are presented as median 
and interquartile range or number and proportions. Results were compared using Mann-Whitney U test, chi-
square test, logistic regression analysis and Cox-proportional-hazard analysis. Differences were considered 
significant when 2-sided p-values ≤0.05.  
 
The 2 primary outcomes were (i) sensitivity, specificity, and positive (PPV) and negative predictive values 
(NPV) of abnormal CMAP, SNAP and SEA for weakness (MRC sum-score<48) and (ii) the predictive value for 
1-year mortality of abnormal electrophysiology results, documented at first evaluation. Data on index and 
reference test are reported according to the Standards for Reporting of Diagnostic Accuracy [21]. 
 
First, incidence of abnormal CMAP, SNAP and SEA was determined in the total screened population and in the 
432 cooperative patients tested for weakness. In the latter subgroup, sensitivity, specificity PPV and NPV of 
abnormal CMAP, SNAP and SEA for weakness were analyzed at the first and second electrophysiological 
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evaluation. Second, association between 1-year mortality and abnormal findings on the first electrophysiological 
screening was assessed by univariate analysis and, when significant, multivariate analyses were performed 
correcting for weakness and other risk factors. Baseline risk factors for 1-year mortality, risk factors to which 
patients were exposed in ICU prior to first electrophysiological assessment (including new infection, treatment 
with neuromuscular blocking agents, duration of corticosteroid administration and duration of mechanical 
ventilation), and the site of electrophysiogical testing, were identified by univariate regression analysis (p<0.2) 
(Table E2).  
 
Multivariate logistic regression analysis of the screened population was performed in 2 steps, first assessing the 
independent predictive value of any abnormal electrophysiological result corrected for weakness, and second 
further correcting for other pre-existing and ICU-acquired risk factors. Risk factors were assigned to the final 
model with use of a backward method (likelihood ratio, probability for enter 0.1, removal 0.2). Model 
performance is reported with the Hosmer-Lemeshow test, c-statistic and visualized by the ROC curve. To 
exclude excessive correlation that might prevent obtaining useful information we checked correlation 
coefficients [22] and performed a forward (likelihood ratio) multiple regression analysis [23]. As MRC-sum <48 
remains an arbitrary limit, we planned post-hoc determination of its optimal cut-off for 1-year mortality and used 
this to repeat the analysis.  
 
To further examine whether weakness and electrophysiology hold different information for long-term outcome, 
patients were categorized into 4 groups according to MRC and electrophysiology. Cox-proportional-hazard 
analysis for 1-year survival was performed for these groups, corrected for the covariates identified in the 
multivariate logistic regression model. The time variable entered was calculated from the time of MRC 
evaluation or electrophysiological testing, which ever came last, up to 1 year after ICU admission.  
 
 
RESULTS 
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Patient characteristics 
 
Electrophysiological screening was performed in 730 patients (online Figure E1) on median day 8 (IQR 8-8). 
This comprised 88 short-stay and 642 long-stay patients. Baseline and outcome variables are depicted in Table 
1&E3.  
In 432 patients, MRC sum-score was also obtained. In this subset, electrophysiological testing was performed on 
day 8 (IQR 8-9) and MRC sum-score on day 10 (IQR 8-14). The delay from electrophysiological testing up to 
the clinical evaluation was 2 days (IQR 0-6). This subgroup clearly differed from the subgroup that could not be 
clinically tested (Table 1).  
 
Diagnostic properties of electrophysiological screening for clinical weakness 
 
In the total population of 730 patients, abnormal CMAPs, SNAPs and SEA occurred in respectively 75.5%, 
11.1% and 20.4% of patients (Table 2). Inevitably, analyses of diagnostic properties of these features was 
performed in the 432 patients who received both MRC and electrophysiology assessment on day 8. The 
incidence of abnormal CMAP and SEA was somewhat lower in the cooperative subgroup with MRC sum-score 
(Table 2).  
 
Reduced CMAP on day 8 had high sensitivity (88.6%), high NPV (80.5%) but low specificity (41.0%) for 
weakness at first examination (Table 2). Reduced SNAP had a low incidence and very low sensitivity for 
detecting weakness (13.6%), although it was highly specific (93.5%). Abnormal SEA exhibited a similar pattern 
with specificity of 89.3% but only 20.7% sensitivity. No single or combined (data not shown) 
electrophysiological feature exhibited high sensitivity and high specificity for detecting weakness on day 8. 
 
When also taking the second electrophysiological screening on day 15 (IQR: 15-15) into account, the incidence 
of electrophysiological abnormalities increased. Abnormal SNAP or the presence of SEA then revealed a very 
high PPV (91.7% and 80.0%, respectively), whereas the NPV of abnormal CMAP decreased (54.5%). Also on 
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day 15, combination of electrophysiological features did not substantially improve diagnostic properties (data 
not shown). 
 
Predictive value of electrophysiological screening for 1-year mortality 
 
In univariate analysis, only CMAP on day 8 was significantly associated with 1-year mortality (Table E4). 
Patients with abnormal CMAP had higher 1-year mortality than patients with normal CMAP (35.6% versus 
15.2%, p<0.001). This difference was present among patients with (26.2% versus 8.0%, p<0.001) and without 
MRC (48.2% versus 29.3%, p=0.010) (Table E5). Also other outcomes were worse for patients with abnormal as 
compared to normal CMAP (Table E5). 
 
In multivariate analysis, adding weakness to the model revealed that both abnormal CMAP and weakness were 
independently associated with 1-year mortality (Table 3). Further adding the other risk factors, including 
baseline risk factors among which co-morbidities, ICU exposures and site of electrophysiological assessment did 
not alter this result (final OR for abnormal CMAP: 2.463, 95%CI: 1.113-5.452, p=0.026 and for weakness: 
1.955, 95% CI: 1.116-3.425, p=0.019). None of the risk factors to which patients were exposed in ICU prior to 
electrophysiological screening remained associated with 1-year mortality in the multivariate model (Table 3) 
with a Hosmer-Lemeshow test p=0.147 and c-statistic = 0.779 (95%CI: 0.730-0.829) (Figure E2). The forward 
regression model retained the same factors as the backward model. Sensitivity analyses, using the optimal 
discriminating MRC sum-score cut-off for 1-year mortality of 53 yielded similar results (data not shown). 
 
Cox-proportional hazard analysis of survival within the first year following ICU admission further confirmed 
that patients with reduced CMAP but no weakness had a higher likelihood for earlier death (HR: 2.818, 95% CI: 
1.074-7.391, p=0.035) as compared to patients with normal CMAP and no weakness. The same was true for 
patients with both weakness and abnormal CMAP (HR: 4.773, 95% CI: 1.882-12.106 p=0.001) (Figure 3).  
 
 
DISCUSSION 
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We showed that reduced CMAP on screening electrophysiological testing 8 days after ICU admission in a 
heterogeneous population of critically ill patients, is highly sensitive but not specific for weakness, with a high 
NPV for weakness. This suggests that early abnormal CMAP reflects neuromuscular alterations that are at least 
in part distinct from weakness. However, when repeated on day 15 in ICU, any abnormal SNAP or the presence 
of SEA revealed a high PPV for weakness. The observation that abnormal CMAP on day 8 remained 
significantly associated with 1-year mortality in multivariate analysis, independent of weakness and other risk 
factors, further supports that these pathophysiological alterations are important for longer-term outcome.  
 
Accuracy of simplified electrophysiological testing to detect critical illness polyneuropathy (CIP) or myopathy 
(CIM) as defined by extensive electrophysiological testing was evaluated previously. Latronico et al. found that 
peroneal nerve CMAP had high sensitivity [19, 24] and specificity [24] for such a diagnosis based on full 
electrophysiological testing. Moss et al. found that combining peroneal and sural amplitudes further increased 
accuracy [15]. The current study differs from previous investigations by assessing diagnostic properties of 
simplified electrophysiological screening for weakness and its predictive value for longer-term outcome. 
 
We found that predictive properties of electrophysiological screening for weakness depend on the time after 
onset of critical illness when tests were performed. Normal CMAP one week after onset of critical illness 
allowed excluding weakness with a high NPV, but this property was not maintained later on. Our findings on 
early CMAP results correspond with other reports. Weber-Carstens [25] found in 44 patients a sensitivity of 92% 
and specificity of 44%. Similarly, Wieske et al. found in 35 patients that both ulnar and peroneal CMAP 
reduction had 100% sensitivity but respectively 0% and 31% specificity to detect weakness [26]. This concurs 
with a higher incidence of electrophysiological abnormalities as compared to weakness in critical illness [27, 
28]. The early high incidence of abnormal CMAP, presumed to reflect both myopathies and neuropathies, 
suggests that this electrophysiological finding captures more than the problem of weakness.  
 
In contrast, abnormal SNAP documented later during critical illness, which may indicated neuropathy, allowed 
diagnosing weakness with a high PPV, which has not been reported earlier.  This high PPV of abnormal SNAP is 
in line with Lefaucher et al. [29] who reported reduced SNAPs in 17/30 patients diagnosed with weakness about 
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two weeks after onset of illness. Zifko et al. [30] found reduced SNAPs in 71% of 62 patients with weakness 40 
days after ICU admission. The higher incidence of abnormal SNAP in both studies as compared with our study is 
explained by the selection of weak patients, referred for electrophysiology rather than systematically screened.  
 
We found a high PPV of SEA for weakness later during critical illness. This is in line with Weber-Carstens et al 
[25], who reported a specificity of 93% and sensitivity of 48% for detection of weakness by SEA using repetitive 
weekly screening. SEA, which may occur both in neuropathy and myopathy [13], develops later than abnormal 
CMAP [27, 31, 32] and incidence increases with duration of ICU stay [33, 34]. In two RCTs, tight glucose 
control reduced the incidence of SEA approximately by half [33, 34]. We here document a similar incidence as 
in the tight glucose control arm of these studies, possibly explained by the routine implementation of tight 
glucose control.  
 
To the best of our knowledge, this study is the first to demonstrate that abnormal CMAP 8 days after ICU 
admission was independently associated with 1-year mortality. This was true independent of weakness. Earlier 
studies reported that electrophysiological signs of CIP and CIM were related with poor short-term prognosis, 
including prolonged ICU and hospital stay, prolonged mechanical ventilation, prolonged rehabilitation and 
increased hospital mortality [15, 35-40] which we here confirmed. Others suggested that this merely reflected 
illness severity [19, 30]. One study of 50 patients also examined the association of electrophysiological 
abnormalities with 1-year mortality but did not find a significant effect, possibly related to lack of power [38]. 
Our findings that abnormal CMAP was independently associated with 1-year mortality, an outcome clearly 
exceeding the index hospitalization, are therefore novel. This opens perspectives for identification of patients 
who might benefit from future interventions to improve outcome. As such, electrophysiology appears to hold 
information required for screening tools for ICU-acquired weakness, as recently stated by the ATS [2]. 
The reason why abnormal CMAP was related to 1-year mortality, independent of other risk factors, remains 
speculative as we did not prospectively evaluate causes of death. The most obvious explanation that reduced 
CMAP predicts weakness, which by itself contributes to 1-year mortality, was invalidated as the association 
between reduced CMAP and 1-year mortality was independent of weakness. This suggests that CMAP reduction 
and weakness possibly identify different, though overlapping, phenotypes of neuromuscular involvement, as 
recently hypothesized [14]. Alternatively, this could point to subclinical weakness not captured by the MRC 
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sum-score. CMAP reduction, reflecting derangement of excitable nerve/muscle tissue, can be an early biological 
sign, according to the theory of bioenergetic failure [19, 41]. Finally, reduced CMAPs could carry information 
about pathophysiological alterations determining longer-term outcome, not necessarily related to weakness. This 
should be further investigated mechanistically.  
 
This study has some limitations and strengths. First, we only performed screening electrophysiological tests as 
we aimed to examine a large ICU population. Therefore, sophisticated tests such as direct muscle stimulation, 
which could have differentiated between neuropathy and myopathy [27, 29, 42, 43], have both high sensitivity 
and specificity for weakness and may precede the diagnosis of weakness by a week [25] were not feasible. For 
similar reasons, also follow-up testing including voluntary muscle contraction was not systematically performed. 
Hence, we cannot differentiate between the role of neuropathy and myopathy in the association with 1-year 
mortality. We also a priori chose to collect amplitudes as dichotomous data, analogously to other studies 
evaluating electrophysiology as a screening tool [19, 24]. In addition, we used alternative nerves if the standard 
nerves were not evaluable. As reference values depend on the nerves evaluated, dichotomization allowed us to 
cope with this issue. We cannot exclude that use of absolute values would have provided additional information. 
All electrophysiological data were protocolized by a single electrophysiologist, which may limit generalizability. 
The case-mix was mainly surgical ICU patients with 27.8% cardiac surgery patients. Diagnostic properties may 
depend on case mix and severity of weakness. Also, we cannot exclude bias from selection of patients who were 
screened as compared to those in whom patient or assessor was not available. Finally, we corrected as much as 
possible for premorbid risk factors and severity of illness. We cannot exclude that other unknown conditions 
brought about a reduced CMAP and contributed to the higher risk of 1-year mortality, as premorbid functional 
assessment or baseline nerve conduction studies were not available [15]. The strengths of this study are the large 
sample size, its prospective design, the systematic and repeated screening electrophysiology and concomitant 
MRC sum-score measurements. There is no gold standard for diagnosing ICU-related neuromuscular 
complications but, as a more reliable test has not yet emerged, MRC-sum <48 was regarded as the reference 
standard by the ATS [2]. 
 
In conclusion, early during critical illness, CMAP had a high NPV for the diagnosis of weakness whereas later, 
SNAP and SEA revealed a high PPV. One week after onset of critical illness, abnormal CMAP was the only 
electrophysiological characteristic associated with 1-year mortality, independent of weakness and other risk 
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factors. This suggests that CMAP may carry information about longer-term outcome and could be useful to 
identify patients for future interventional studies aiming to improve outcomes.  
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Figure legends 
 
Figure 1: Screening electrophysiological tests 
CMAP: compound muscle action potential; SNAP: sensory nerve action potential; SEA: spontaneous electrical 
activity 
 
Figure 2: Patient flow chart 
ICU: intensive care unit; NMD: neuromuscular disease; MRC: Medical Research Council 
 
Figure 3: Cox regression estimates for survival in the first year after ICU admission. 
The survival curve visually displays the model predicted survival time for the ‘average’ patient (this means with 
other covariates fixed at their average values) according to the results of CMAP at day 8 and presence or absence 
of weakness at first MRC-sum score measured from day 8 onwards. Covariates entered in the model are those 
that were retained by the multivariate logistic regression model for 1 year survival and included age, BMI<25 or 
>40, malignancy and sepsis upon admission. The time variable entered in the model was calculated from the 
time of electrophysiological testing or MRC sum-score, which ever came last, up to 1 year after ICU admission. 
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Table 1. Baseline characteristics and outcomes for patients receiving electrophysiological screening 
 Total population With MRC 
Without 
MRC P-value 
 N=730 N=432 N=298  
Baseline characteristics     
Age, years, median (IQR) 64 (53-74) 64 (53-73) 64 (54-75) 0.233 
APACHE II score, median (IQR) 32 (24-38) 33 (23-38) 32 (26-39) 0.242 
Sex, male sex, N (%) 462 (63.2) 253 (58.6) 209 (70.1) 0.001 
BMI<25 or>40, N (%) 371 (50.8) 229 (53.0) 142 (47.7) 0.155 
NRS <5, N (%) 506 (69.3) 298 (69.0) 208 (69.8) 0.814 
Diabetes mellitus, N (%) 127 (17.4) 69 (16.0) 58 (19.5) 0.221 
Malignancy, N (%) 183 (25.1) 113 (26.2) 70 (23.5) 0.414 
Pre-admission dialysis, N (%) 12 (1.6) 6 (1.4) 6 (2.0) 0.514 
Sepsis, N (%) 355 (48.6) 207 (47.9) 148 (49.7) 0.642 
Admission category 
Cardiac surgery, N (%) 
Elective surgery, N (%) 
Emergent surgery, N (%) 
MICU, N (%) 
 
203 (27.8) 
29 (4.0) 
348 (47.7) 
150 (20.5) 
 
134 (31.0) 
22 (5.1) 
204 (47.2) 
72 (16.7) 
 
69 (23.2) 
7 (2.3) 
144 (48.3) 
78 (26.2) 
0.002 
Randomization to late PN, N (%) 363 (49.7) 220 (50.9) 143 (48.0) 0.435 
Outcomes     
Duration MV, days, median (IQR) 9 (5-18) 8 (4-17) 11 (6-18) 0.002 
Time to live weaning from MV, days, median 
(IQR) 
10 (5-24) 8 (4-18) 13 (6-283) <0.001 
ICU length of stay, days, median (IQR) 14 (10-23) 14 (9-26) 14 (10-22) 0.918 
Time to live ICU discharge, days, median (IQR) 15 (10-33) 14 (9-26) 18 (10-283) <0.001 
ICU mortality (N, %) 103 (14.1) 21 (4.9) 82 (27.5) <0.001 
Hospital length of stay, days, median (IQR)a 33 (21-55) 35 (21-58) 31 (20-49) 0.016 
Time to live hospital discharge, days, median (IQR) 47 (26-207) 39 (24-84) 76 (31-380) <0.001 
Hospital mortality (N, %) 176 (24.1) 54 (12.5) 122 (40.9) <0.001 
1y mortality (N, %)b 230 (31.6) 95 (22.0) 135 (45.5) <0.001 
Abbreviations: MRC: Medical Research Council; IQR: interquartile range; APACHE II: acute physiology and 
chronic health evaluation; BMI: body mass index; NRS: nutritional risk score; MICU: medical ICU; ICU: intensive 
care unit; MV: mechanical ventilation; PN: parenteral nutrition 
aHospital stay was shorter, explained by higher hospital mortality and longer time to live hospital discharge 
b1y-survival status is unknown for 2 foreigners 
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Table 2. Incidence of electrophysiological abnormalities on the first and second evaluation and their predictive value for ICUAW 
 
Incidence in total 
population 
Incidence in patients 
with MRC sum-score 
Sensitivity 
(95%CI) 
Specificity 
(95%CI) 
Positive  
predictive value 
(95%CI) 
Negative 
predictive value 
(95%CI) 
First electrophysiological screening N=730 N= 432     
CMAP reduced or absent 527/698 (75.5%) 302/415 (72.8%) 88.6% (83.0-92.6) 41.0% (34.5-47.8) 56.6% (50.8-62.3) 80.5% (71.8-87.1) 
SNAP reduced or absent 71/638 (11.1%) 37/384 (9.6%) 13.6% (9.0-19.9) 93.5% (89.1-96.3) 62.2% (44.8-77.1) 57.9% (52.5-63.1) 
Abnormal SEA 146/716 (20.4%) 65/423 (15.4%) 20.7% (15.4-27.2) 89.3% (84.4-92.9) 63.1% (50.2-74.4) 56.1% (50.8-61.3) 
Second electrophysiological 
screening N=327 N=195     
CMAP reduced or absent 284/320 (88.8%) 167/189 (88.4%) 92.3% (85.9-96.0) 20.3% (11.4-33.2) 71.9% (64.3-78.4) 54.5% (32.6-74.9) 
SNAP reduced or absent 45/290 (15.5%) 24/172 (14.0%) 18.5% (12.2-26.9) 96.2% (85.9-99.3) 91.7% (71.5-98.5) 34.5% (27.0-42.8) 
Abnormal SEA 129/324 (39.8%) 55/193 (28.5%) 33.1% (25.3-41.8) 81.7% (69.1-90.1) 80.0% (66.6-89.1) 35.5% (27.7-44.2) 
Abbreviations: MRC: Medical Research Council; CMAP: compound muscle action potential; SNAP: sensory nerve action potential; SEA: spontaneous electrical activity 
Different denominators are due to technical issues precluding evaluation of certain electrophysiological tests in some patients 
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Table 3. Multivariate logistic regression analysis for the risk of death 1 year after ICU admission 
 OR p value 
A. Uncorrected    
Abnormal CMAP 3.076 (1.954-4.844) <0.001 
B. Corrected for weakness   
Abnormal CMAP 3.115 (1.466-6.616) 0.003 
MRC sum-score <48 2.128 (1.274-3.556) 0.004 
C. Corrected for weakness, baseline risk factorsa, ICU risk factors prior to electrophysiological 
testingb and site of testing 
Abnormal CMAP 2.463 (1.113-5.452) 0.026 
MRC sum-score <48 1.955 (1.116-3.425) 0.019 
Age 1.045 (1.022-1.069) <0.001 
BMI <25 or >40 1.800 (1.045-3.099) 0.034 
Malignancy 2.892 (1.669-5.011) <0.001 
Sepsis on admission 1.849 (1.056-3.237) 0.032 
NRS≥5 1.508 (0.870-2.614) 0.143 
Abbreviations: OR: odds ratio; CMAP: compound muscle action potential; MRC: Medical Research 
Council; BMI: Body Mass Index; NRS: nutritional risk score 
abaseline risk factors included are: age, BMI, NRS, APACHE II, diagnostic categories, diabetes, 
malignancy, pre-admission dialysis, sepsis on admission 
bICU risk factors prior to electrophysiological screening included are: new infections, neuromuscular 
blocking agents, corticosteroids and duration of mechanical ventilation up to day 8 of ICU admission 
 
 
 22 
Figure 1 
Ne
rv
e c
on
du
ct
io
n 
st
ud
ies
 
Motor nerve conduction studies: 
A peripheral nerve is stimulated and the evoked compound 
muscle action potential (CMAP) is recorded with use of 
surface electrodes overlying a muscle supplied by that 
nerve. CMAP is reduced in neuropathy and myopathy. 
 
 
Median nerve motor study (CMAP) 
 
Sensory nerve conduction studies: 
A peripheral nerve is stimulated and the evoked sensory 
nerve action potential (SNAP) is obtained with surface 
electrodes from a purely sensory distal part of the stimulated 
nerve. SNAP is reduced in neuropathy. As absolute values 
of SNAPs are much smaller than absolute values of CMAPs, 
SNAPs are more affected by limb edema. 
 
 
 
 Median nerve sensory study (SNAP) 
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Electrical muscle activitiy in rest: 
This is registered with use of a concentric needle. Abnormal 
spontaneous electrical activity (SEA) occurs as fibrillation 
potentials and/or positive sharp waves and may be present 
in case of denervation or muscle necrosis. 
 
 
Electromyography of the vastus lateralis of the 
quadriceps muscle 
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Methods 
 
Patients  
 
All patients with known neuromuscular disorders identified prior to ICU admission, or in whom a primary 
neuromuscular disorder was the reason for admission to the ICU were excluded. Among these were patients with 
diabetic polyneuropathy, alcoholic polyneuropathy, other polyneuropathies, steroid induced and other 
myopathies, spinal cord injury, central causes of neuromuscular dysfunction, Guillain Barré syndrome, 
myasthenia gravis, paraneoplastic neuromuscular disease, degenerative neuromuscular disorders, congenital 
disorders. 
 
Electrophysiology 
 
For the nerve conduction studies, 1 standard motor and 1 sensory nerve were evaluated in both upper and lower 
limbs unilaterally. If not evaluable, the contralateral side was used, or else the alternative nerve. For the motor 
nerves, we standardly used the tibial and median nerves, or alternatively the peroneal and ulnar nerves. The 
standard sensory nerves included the median and sural nerves, or alternatively the radial nerve. We used 
reference values generated in the KU Leuven electrophysiology laboratory (Table E1) and defined reduced 
CMAP and SNAP when below the lower limit of normal in both nerves of both limbs [19]. Repetitive 
stimulation of the median nerve at 3 Hz was performed to evaluate the neuromuscular junction, and if abnormal, 
the data of that specific electrophysiological test were excluded from analyses. Needle electromyography in rest 
was performed unilaterally in 1 standard proximal and 1 distal muscle in both upper and lower limbs. If not 
evaluable, the contralateral muscle was evaluated or else the alternative muscle. Standard muscles included 
extensor digitorum communis, biceps brachii, gastrocnemius and vastus lateralis of the quadriceps femoris. The 
alternative muscles included interosseus dorsalis I, pars media of the deltoid muscle, anterior tibial muscle, 
vastus medialis of the quadriceps femoris or rectus femoris. Abundant SEA was defined as the presence of 
 3 
sustained fibrillation potentials and/or positive sharp waves after initial insertional activity in at least 2 muscles 
of at least 2 limbs. 
 
MRC sum-score 
 
MRC sum-score was evaluated as previously described (1). Briefly, cooperation of the patient was evaluated first 
using 5 standardized questions(1). Only when patients responded correctly to all of these, MRC sum-score was 
determined. Peripheral muscle strength was evaluated manually in a proximal, mid and distal muscle group of 
each upper and lower limb. This included abduction of the arm, flexion of the forearm, extension of the wrist, 
flexion of the hip, extension of the knee and dorsal flexion of the foot. All muscle groups were scored between 0 
(no visible/palpable contraction) and 5 (normal muscle strength) and values were summed to obtain an MRC 
sum-score between 0 and 60. Manual muscle testing was performed by one of 2 physiotherapists extensively 
trained prior to the study, with good inter-observer reliability (2). The observers were blinded for results of 
electrophysiological testing. For each patient, we recorded first MRC sum-score determined as the first 
measurement made from day 8 onwards, the time-point that screening for awakening started for every patient. 
ICUAW was diagnosed if MRC sum-score was less than 48 (1). 
 
Figure legends 
 
Figure E1, panel A: Flow diagram CMAP 
Flow diagram providing information on patients undergoing screening electrophysiological testing with CMAP 
as the test under evaluation (index test) and the MRC sum score as a reference test. Weakness was diagnosed 
when MRC sum score < 48. 
CMAP: compound muscle action potential, MRC: Medical Research Council 
 
Figure E1, panel B: Flow diagram SNAP 
Flow diagram providing information on patients undergoing screening electrophysiological testing with SNAP 
as the test under evaluation (index test) and the MRC sum score as a reference test. Weakness was diagnosed 
when MRC sum score < 48. 
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SNAP: sensory nerve action potential, MRC: Medical Research Council 
 
Figure E1, panel C: Flow diagram SEA 
Flow diagram providing information on patients undergoing screening electrophysiological testing with SEA as 
the test under evaluation (index test) and the MRC sum score as a reference test. Weakness was diagnosed when 
MRC sum score < 48. 
SEA: spontaneous electrical activity, MRC: Medical Research Council 
 
Figure E2:  
Receiver operating characteristics for the multivariate regression model on 1-year mortality. 
The curve was constructed by use of predicted probabilities as the test variable and 1 year mortality as the state 
variable. The area under the curve is 0.779 (95%CI: 0.730-0.829) 
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Table E1: Reference values generated in the KU Leuven electrophysiology laboratory, stimulation and recording 
sites for CMAP and SNAP  
  Cut-off Location of stimulation Location of recording 
CMAP Median nerve        < 6000 µV Middle anterior wrist and elbow fold M abductor pollicis brevis 
 Ulnar nerve < 4500 µV Ulnar anterior wrist and medial epicondyle M abductor digiti minimi 
 Peroneal nerve         < 1000 µV Anterior ankle and fibular head M extensor digitorum brevis 
 Tibial nerve < 2500 µV Inner ankle and knee fold M flexor hallucis brevis 
SNAP Median nerve < 4 µV   Middle anterior wrist Palmar index finger 
 Radial nerve < 4 µV   Lateral edge of radius bone Web space between digits I & II 
 Sural nerve < 4 µV   Lateral of Achilles tendon  At lateral malleolus 
CMAP: compound muscle action potential, SNAP: sensory nerve action potential 
SNAPs were measured antidromically with 14 cm distance between stimulation and recording site 
 
 
 
 
Table E2: Univariate regression analysis of risk factors for 1-year mortality in the total EPaNIC 
population 
 
1y non-survivor 
N=743 
1y survivor 
N=3884 
P value 
Baseline characteristic    
Randomization (early PN), N (%) 360/743 (48.5) 1944/3884 (50.1) 0.424 
Age, median (IQR) 70 (60-78) 66 (55-74) <0.001 
Gender, male, N (%) 475/743 (63.9) 2485/3884 (64.0) 0.979 
BMI 25-40, yes, N (%) 348/743 (46.8) 2193/3884 (56.5) <0.001 
NRS >=5, yes, N (%) 272/743 (36.6) 588/3884 (15.1) <0.001 
APACHE II, median (IQR) 32 (22-39) 18 (14-29) <0.001 
Diagnostic categories   <0.001 
Emergent surgery, N (%) 283/743 (38.1) 881/3884 (22.7)  
Elective surgery, N (%) 64/743 (8.6) 213/3884 (5.5)  
Cardiac surgery, N (%) 224/743 (30.1) 2588/3884 (66.6)  
MICU 172/743 (23.1) 202/3884 (5.2)  
Diabetes, yes, N (%)  167/743 (22.5) 640/3884 (16.5) <0.001 
Malignancy, yes, N (%) 259/743 (34.9) 633/3884 (16.3) <0.001 
Dialysis pre-admission, yes, N (%) 23/743 (3.1) 46/3884 (1.2) <0.001 
Sepsis on admission, yes, N (%) 347/743 (46.7) 666/3884 (17.1) <0.001 
ICU risk factors up to day 8 
New infection, yes, N (%) 242/743 (32.6) 604/3884 (15.6) <0.001 
NMBA, yes, N (%)  249/743 (33.5) 488/3884 (12.6) <0.001 
Corticosteroids, days, median (IQR) 0 (0-4) 0 (0-0) <0.001 
Mechanical ventilation, days, median (IQR) 5 (2-8) 2 (1-3) <0.001 
Site of electrophysiological screening    
EMG&NCS performed on ICU, N (%) 217/230 (94.3) 423/498 (84.9) <0.001 
Abbreviations: PN: parenteral nutrition; BMI: Body Mass Index; NRS: Nutritional Risk Score; APACHE II: 
Acute Physiology And Chronic Health Evaluation II; MICU: medical intensive care unit; ICU: intensive care 
unit; NMBA: Neuromuscular Blocking Agents; EMG&NCS: Electromyography and Nerve Conduction Studies. 
Site of electrophysiological screening refers to testing in ICU or on the ward. 
Survival status at 1 year was not available in 13 foreigners 
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Table E3. Baseline and outcome characteristic for patients who received electrophysiological screening 
according to length of stay 
 Random sample short- 
stayer patients evaluated 
on the ward 
N=88 
Long-stay patients 
evaluated in ICU 
  
N= 642 
Baseline characteristics   
Age, years, median (IQR) 64 (53-75) 64 (53-74) 
APACHE II score, median (IQR) 24 (16-33) 33 (26-39) 
Sex, male sex, N (%) 47 (53.4) 415 (64.6) 
BMI<25 or>40, N (%) 46 (52.3) 325 (50.6) 
NRS <5, N (%) 69 (78.4) 437 (68.1) 
Diabetes mellitus, N (%) 18 (20.5) 109 (17) 
Malignancy, N (%) 21 (23.9) 162 (25.2) 
Pre-admission dialysis, N (%) 1 (1.1) 11 (1.7) 
Sepsis, N (%) 16 (18.2) 339 (52.8) 
Admission category 
Cardiac surgery, N (%) 
Elective surgery, N (%) 
Emergent surgery, N (%) 
MICU, N (%) 
31 (35.2) 
8 (9.1) 
39 (44.3) 
10 (11.4) 
172 (26.8) 
21 (3.3) 
309 (48.1) 
140 (21.8) 
Randomization to late PN, N (%) 48 (54.5) 315 (49.1) 
Outcomes   
Duration MV, days, median (IQR) 2 (1-3) 11 (6-19) 
Time to live weaning from MV, days, median (IQR) 2 (1-3) 12 (7-30) 
ICU length of stay, days, median (IQR) 3 (2-4) 16 (11-26) 
Time to live ICU discharge, days, median (IQR) 3 (2-4) 18 (11-40) 
ICU mortality (N, %) 0 (0) 103 (16.0) 
Hospital length of stay, days, median (IQR)a 16 (12-26) 35 (23-58) 
Time to live hospital discharge, days, median (IQR) 16 (12-28) 54 (29-380) 
Hospital mortality (N, %) 4 (4.5) 172 (26.8) 
1y mortality (N, %)b 13 (14.8) 217 (33.9) 
ICUAW (N, %) 3/72 (4.2) 201/360 (55.8) 
CMAP abnormal, (N, %) 45/85 (52.9) 482/613 (78.6) 
Abbreviations: MRC: Medical Research Council; IQR: interquartile range; APACHE II: acute physiology 
and chronic health evaluation; BMI: body mass index; NRS: nutritional risk score; MICU: medical ICU; ICU: 
intensive care unit; MV: mechanical ventilation; PN: parenteral nutrition; ICUAW: intensive care unit 
acquired weakness; CMAP: compound muscle action potential 
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Table E4. Univariate regression analysis of electrophysiological screening examination on day 8 and ICUAW for 1-year mortality 
 Total population N=730 
With MRC sum-score 
N=432 
Without MRC sum-score 
N=298 
 1y non-survivor N= 230 
1y survivor 
N= 498 
P value 1y non-survivor 
N=95 
1y survivor 
N=336 
P value 1y non-survivor 
N=135 
1y survivor 
N=162 
P value 
Electrophysiological data          
abnormal CMAP, N (%) 187/213 (87.8) 339/484 (70.0) <0.001 79/88 (89.8) 223/327 (68.2) <0.001 108/125 (86.4) 116/157 (73.9) 0.010 
abnormal SNAP, N (%) 26/188 (13.8) 45/449 (10.0) 0.164 11/80 (13.8) 26/304 (8.6) 0.161 19/145 (13.1) 15/108 (13.9) 0.856 
SEA present, N (%) 52/226 (23.0) 94/488 (19.3) 0.248 17/93 (18.3) 48/329 (14.6) 0.384 35/133 (26.3) 46/159 (28.9) 0.619 
  Clinical neuromuscular evaluation        
ICUAW, yes, N (%) 62/95 (65.3) 141/336 (42.0) <0.001 62/95 (65.3) 141/336 (42.0) <0.001 - - - 
CMAP: Compound Muscle Action Potential; SEA: Spontaneous Electrical Activity; SNAP: Sensory Nerve Action Potential; ICUAW: Intensive Care Unit-Acquired Weakness 
1-y survival status is unknown in 2 foreigners 
Varying denominators are due to technical limitations precluding certain electrophysiological tests in some patients 
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Table E5. Outcomes according to results of CMAP on electrophysiological screening performed on day 8±1 after ICU admission 
 Total population With MRC Without MRC 
 Abnormal 
CMAP 
Normal 
CMAP 
p-value Abnormal 
CMAP 
Normal 
CMAP 
p-value Abnormal 
CMAP 
Normal 
CMAP 
p-value 
 N=527 N=171  N=302 N=113  N=225 N=58  
First MRC sum-score, median (IQR) 46 (38-52) 53 (48-58) <0.001 46 (38-52) 53 (48-58) <0.001 - - - 
First MRC sum-score <48, N (%) 171 (56.6) 22 (19.5) <0.001 171 (56.6) 22 (19.5) <.0001 - - - 
Duration MV, days, median (IQR) 10 (6-19) 7 (2-12) <0.001 9 (5-19) 5 (2-11) <0.001 11 (6-19) 9 (5-15) 0.189 
Time-to-live weaning from MV, days, median (IQR) 11 (6-27) 7 (2-13) <0.001 9 (5-20) 5 (2-11) <0.001 14 (7-283) 10 (5-20) 0.039 
ICU length of stay, days, median (IQR) 15 (10-25) 12 (8-18) <0.001 15 (10-28) 10 (4-18) <0.001 14 (10-22) 13 (9-21) 0.449 
Time-to-live ICU discharge, days, median (IQR) 17 (10-38) 12 (8-19) <0.001 16 (10-29) 10 (4-18) <0.001 18 (11-283) 14 (10-27) 0.078 
ICU mortality, N (%) 79 (15.0) 13 (7.6) 0.013 16 (5.3) 2 (1.8) 0.126 63 (28.0) 11 (19.0) 0.163 
Hospital length of stay, days, median (IQR) 35 (22-61) 27 (15-42) <0.001 39 (25-66) 26 (14-41) <0.001 31 (20-51) 28 (21-43) 0.388 
Time-to-live hospital discharge, days, median (IQR) 54 (28-380) 29 (17-50) <0.001 46 (27-96) 27 (14-43) <0.001 94 (33-380) 39 (23-380) 0.001 
Hospital mortality, N (%) 142 (26.9) 19 (11.1) <0.001 45 (14.9) 4 (3.5) 0.001 97 (43.1) 15 (25.9) 0.017 
1-y mortality, N (%) 187 (35.6) 26 (15.2) <0.001 79 (26.2) 9 (8.0) <0.001 108 (48.2) 17 (29.3) 0.010 
CMAP: Compound Muscle Action Potential; MRC: Medical Research Council; MV: mechanical ventilation; IQR: interquartile range 
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Figure E1, panel A 
  
 
 
Figure E1, panel B 
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Figure E1, panel C 
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